Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey

Public research footprint of Rutgers Cancer Institute of New Jersey, compiled from the ClinicalTrials.gov public registry.

755

Registered studies

373

Active

155

Recruiting now

259

Completed

104

Stopped or withdrawn

Most-studied conditions

Acute Myeloid Leukemia · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · Recurrent Fallopian Tube Carcinoma · Recurrent Primary Peritoneal Carcinoma

Recently updated registry entries

NCT03712605 — Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After… (Active Not Recruiting)
NCT05675410 — A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… (Recruiting)
NCT01142388 — Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Rutgers Cancer Institute of New Jersey?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.